Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Reboxetine in seasonal affective disorder: an open trial
Autore:
Hilger, E; Willeit, M; Praschak-Rieder, N; Stastny, J; Neumeister, A; Kasper, S;
Indirizzi:
Univ Vienna, Dept Gen Psychiat, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 t Gen Psychiat, A-1090 Vienna, Austria
Titolo Testata:
EUROPEAN NEUROPSYCHOPHARMACOLOGY
fascicolo: 1, volume: 11, anno: 2001,
pagine: 1 - 5
SICI:
0924-977X(200102)11:1<1:RISADA>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
LIGHT THERAPY; WINTER DEPRESSION; BRIGHT LIGHT; TRYPTOPHAN DEPLETION; AVAILABILITY; BINDING;
Keywords:
seasonal affective disorder; depression; atypical symptoms; noradrenaline; reboxetine;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
28
Recensione:
Indirizzi per estratti:
Indirizzo: Kasper, S Univ Vienna, Dept Gen Psychiat, Waehringer Guertel 18-20, A-1090Vienna, Austria Univ Vienna Waehringer Guertel 18-20 Vienna Austria A-1090 tria
Citazione:
E. Hilger et al., "Reboxetine in seasonal affective disorder: an open trial", EUR NEUROPS, 11(1), 2001, pp. 1-5

Abstract

Seasonal affective disorder (SAD), winter type, is a condition characterized by the annual recurrence of depressive episodes during fall/winter, alternating with spring/summer euthymia or hypomania. Various neurotransmittershave been implicated in the etiology of SAD, the strongest evidence involving serotonin. Recently, increasing attention has been paid to the potential role of catecholaminergic pathways in the pathophysiology of SAD. We investigated the efficacy and tolerability of reboxetine, a selective noradrenaline inhibitor, in patients with SAD. Eleven out of sixteen patients who were included in a 6-week drug surveillance during winter season experienced full remission of depressive symptoms. Nine patients reported a rapid relief of preexistent severe atypical depressive symptoms within the first treatment week. Reboxetine might therefore be an effective and well-tolerated treatment option for SAD patients. In conclusion, our preliminary results arein line with evidence from recent studies suggesting that catecholaminergic systems might also be involved in the pathophysiology of SAD. (C) 2001 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 08:29:14